(FEMY) Femasys Inc. Business Model Canvas Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(FEMY) Femasys Inc. Complete Analysis Pack
Femasys Inc. Business Model Canvas: Growth Drivers at a Glance
Explore how Femasys Inc. turns innovation into value with a clear, concise Business Model Canvas. From customer segments to revenue streams, this strategic snapshot helps you quickly see what drives the business and where its growth potential lies. Get the full canvas to unlock deeper, company-specific insights.
Partnerships
OB-GYN provider network
Femasys’ OB-GYN network is the main route to adoption for its infertility products, because these clinicians can place the company’s non-surgical devices during routine office visits. With about 18,000 U.S. obstetrician-gynecologists, this channel gives Femasys direct access to the doctors who already manage fertility and women’s health care.
Reproductive endocrinologists
Reproductive endocrinologists are core partners for Femasys Inc. because they use its infertility products in fertility workups and treatment plans. With infertility affecting about 1 in 6 adults worldwide, these specialists give the company clinical credibility and direct access to high-need patients.
Women’s healthcare provider organizations
Women’s healthcare provider organizations help Femasys place products across multiple practices, so one buying decision can scale to many clinics. This matters in a U.S. women’s health market that serves millions of visits each year, and it supports broader access for Femasys’ portfolio without adding many separate sales calls.
International distributors
FemVue’s presence in the U.S., Europe, Canada, and Japan points to at least 4 commercial markets, so Femasys Inc. depends on overseas distributors to sell, ship, and support the product outside its home base. That partner network matters because it widens access, cuts market-entry friction, and helps scale a women’s health product across regulated regions.
- 4 market regions for FemVue
- Needs overseas distribution support
- Extends access beyond the U.S.
Clinical and regulatory partners
Femasys Inc. depends on clinical sites and regulatory partners because its device candidates and diagnostics still need clinical validation before commercialization. These partners help generate the data regulators need, which is critical for moving products through development and into market approval.
- Clinical sites support trial enrollment
- Regulatory experts guide submissions
- Validation speeds market entry
Femasys Builds Growth Through OB-GYNs, Trials, and Global Distributors
Femasys Inc. leans on OB-GYNs, reproductive endocrinologists, and women’s health group practices to place its infertility products in routine care. It also needs clinical sites and regulatory partners to run trials and support submissions, while overseas distributors help FemVue reach at least 4 markets outside the U.S.
| Partner | Role | Data |
|---|---|---|
| OB-GYNs | Adoption channel | 18,000 U.S. doctors |
| FemVue distributors | Foreign sales | 4 market regions |
What is included in the product
Detailed Word Document
A concise Business Model Canvas of Femasys Inc. highlighting its women’s health devices, customers, channels, and growth strategy.
Customizable Excel Spreadsheet
Clarifies Femasys Inc.’s pain-point reliever in a concise, editable snapshot for fast review.
Reference Sources
Provides a clear source trail for Femasys Inc. that boosts credibility and speeds decision-making.
Activities
Women’s health device development
Femasys Inc. centers its key activity on women’s health device development, building non-surgical technologies for contraception, infertility, and diagnostics. Product innovation drives the business: the portfolio spans FemaSeed infertility, FemBloc contraception, and FemVue/FemCerv diagnostic devices.
Clinical testing and validation
Clinical testing and validation are central for Femasys Inc, because the 4 core products, FemBloc, FemChec, FemCerv, and FemEMB, all need clinical evidence to show safety and performance. Strong data improves market acceptance and supports regulatory progress, which is critical for device adoption.
Regulatory and quality compliance
Femasys Inc. must keep its devices aligned with U.S. FDA rules under 21 CFR Part 820 and international standards such as ISO 13485, because quality systems drive consistent device performance and lower recall risk. This compliance work also supports commercialization across multiple countries, where each market can require separate evidence, labels, and filings.
Commercial sales to providers
Femasys sells directly to OB-GYNs, allied healthcare professionals, and reproductive endocrinologists, and the real job is getting office-based adoption. In FY2025, that commercial motion was still early-stage, so each new provider account is a direct revenue driver.
- Direct provider selling
- Office-based use
- Adoption drives revenue
International market expansion
International market expansion is a core activity for Femasys Inc. because FemVue is commercialized in the U.S. and in multiple regions outside it, so the company must manage region-specific regulation, distribution, and sales execution to grow revenue and brand reach.
- FemVue sells in the U.S. and abroad
- Local commercialization drives reach
- Geography-specific execution matters
Femasys Advances Women’s Health Innovation and Provider Adoption
Femasys Inc.’s key activities are R&D, clinical validation, and regulatory work for its 4 core women’s health devices: FemBloc, FemChec, FemCerv, and FemEMB. In FY2025, the company also focused on direct provider selling and office-based adoption, with each new OB-GYN account helping drive early revenue.
| Key activity | FY2025 focus |
|---|---|
| R&D | 4 core products |
| Clinical evidence | Safety and performance |
| Commercialization | Direct provider adoption |
Full Version Awaits
Business Model Canvas
The Femasys Inc. Business Model Canvas previewed here is the exact document you’ll receive after purchase. It’s not a sample or mockup—what you see is a real snapshot from the final file, with the same structure, formatting, and content. Once you buy, you’ll download the complete version ready to edit, present, or share.
Resources
2004-founded company
Founded in 2004, Femasys brings 22 years of operating history to women’s health, which supports deeper device development know-how and a more established base for R&D, regulatory work, and commercialization. In 2025/2026, that long runway still matters because medical device firms often need years of iterative testing and clinical proof before scaling.
Suwanee, Georgia headquarters
Femasys Inc. is based in Suwanee, Georgia, and that U.S. headquarters centralizes management, operations, and commercialization from one domestic base. For a company that reported $0.8 million in revenue for 2024, the Suwanee site anchors execution close to its U.S. market, partners, and regulators.
Non-surgical product portfolio
Femasys Inc.’s non-surgical portfolio spans FemBloc, FemChec, FemaSeed, FemCerv, FemEMB, and FemVue, covering contraception, infertility, and diagnostics in one product set. This breadth is a key asset: as of the latest public filings, the pipeline targets 3 core women’s health markets and supports multiple revenue paths, not just one product line.
Women’s health know-how
Femasys Inc.’s key resource is women’s health know-how across fertility, contraception, and uterine diagnostics. That matters in a market where WHO says about 1 in 6 adults faces infertility, and uterine fibroids affect up to 70% of women by age 50, so focused expertise can set the platform apart.
- Fertility, contraception, diagnostics
- Targets high-need women’s care
- Built for differentiation
International market presence
Femasys Inc.'s international market presence is already a commercial asset: FemVue is sold in the U.S., Europe, Canada, and Japan, giving the Company a multi-region base it can reuse for new products. That reach lowers launch friction and can help expand distribution without starting from zero in each market.
- FemVue in 4 major markets
- Re-usable regulatory and sales reach
- Supports future product expansion
Femasys’ 22-Year Health IP Powers Global FemVue Reach
Femasys Inc.’s key resources are its women’s health IP, its 22-year device development base since 2004, and its U.S. Suwanee, Georgia hub. In 2024, it reported $0.8 million in revenue, while FemVue already has reach in the U.S., Europe, Canada, and Japan.
| Resource | Data |
|---|---|
| History | 22 years |
| 2024 revenue | $0.8M |
| FemVue markets | 4 |
Value Propositions
Permanent contraception
FemBloc and FemChec target permanent contraception needs with a non-surgical path in women’s health, which can appeal to patients who want durable birth control without surgery. The value is clear in a large need area: the CDC says female sterilization remains one of the most used long-acting birth control choices in the U.S.
Artificial insemination support
FemaSeed is an artificial insemination option that supports infertility care in a less invasive format, helping clinics offer office-based treatment instead of more complex procedures. WHO says about 1 in 6 adults face infertility, so this need is large and persistent.
Biopsy-based cervical diagnosis
FemCerv gives clinicians a focused office tool for endocervical curettage, supporting biopsy-based cervical diagnosis when precise tissue sampling is needed. Cervical cancer still drives about 660,000 new cases and 350,000 deaths a year worldwide, so targeted diagnostic sampling remains clinically important.
Endometrial sampling candidate
FemEMB is an endometrial sampling device built to help detect uterine cancer, a gap that matters because the American Cancer Society projected 67,880 new uterine cancer cases and 13,250 deaths in the U.S. in 2024. For Femasys Inc., this positions FemEMB as a low-cost, office-based diagnostic option aimed at earlier evaluation in women’s health.
- Targets endometrial sampling
- Supports uterine cancer detection
- Addresses a major diagnostic gap
Non-surgical care platform
Femasys Inc. sells a non-surgical care platform built around women’s health needs across contraception, infertility, and diagnostics. Its product set, including FemaSeed, FemBloc, and FemVue, gives the Company a single-platform value proposition that can reach multiple care points without surgery.
- Non-surgical care across key women’s health uses
- One platform, three linked product areas
- Broadens use beyond one procedure category
Femasys Targets Big Unmet Needs in Women’s Health
Femasys Inc. sells office-based, non-surgical women’s health products for contraception, infertility, and diagnostics, led by FemBloc, FemaSeed, FemCerv, and FemEMB. The pitch fits large unmet need: WHO says 1 in 6 adults face infertility, and the American Cancer Society projected 67,880 U.S. uterine cancer cases in 2024.
Customer Relationships
Physician-directed selling
Femasys uses physician-directed selling in clinician-led care settings, so OB-GYNs and reproductive endocrinologists drive adoption and product choice. The relationship is B2B and professional, built around clinical evidence, training, and trust rather than consumer marketing; that fits a specialty medtech model where one provider can influence many patient cases.
Clinical education support
Clinical education support helps Femasys Inc. drive adoption because provider training shapes how well clinicians use, place, and match each device to the right patient. It also builds confidence for office-based care, which matters as the Company scales adoption across its women’s health portfolio.
Product-focused support
Product-focused support is central for Femasys Inc. because medical device buyers need hands-on help with use, setup, and workflow fit, especially for non-surgical products like FEMBloc. In medtech, smoother onboarding cuts adoption friction and can reduce training time, which matters when each site must adopt a new procedure with little room for error.
Healthcare organization accounts
Women’s healthcare provider organizations are Femasys Inc.’s direct customers, so sales depend on coordinated purchasing, training, and account management across clinics and hospital systems. These relationships can last, and repeat orders tend to come from the same accounts once the products are adopted.
- Direct B2B healthcare accounts
- Needs coordinated purchasing
- Supports repeat sales
International partner management
FemVue’s international partner management matters because access depends on local distributors and market support across regions, not one global playbook. Femasys reported only $0.1 million in revenue in Q1 2025, so keeping country partners aligned is key to preserving multi-country access and scaling sales without building a large direct force.
- Regional coordination keeps FemVue available across markets.
- Partner support differs by country and regulator.
- Strong ties help protect access and sales reach.
Clinician-Led Sales Matter as Femasys Revenue Stays Tiny
Femasys Inc. keeps customer ties clinician-led and B2B: OB-GYNs, reproductive endocrinologists, and provider groups shape adoption through evidence, onboarding, and hands-on training. That support matters because the Company reported only $0.1 million revenue in Q1 2025, so each account must convert carefully.
| Customer relationship | Why it matters | Latest data |
|---|---|---|
| Physician-led B2B | Drives use and trust | Q1 2025 revenue: $0.1M |
Channels
Direct provider sales
Femasys sells its infertility products directly to OB-GYNs and allied professionals, a fit for clinician adoption because the channel lets the company train providers and build named accounts one by one. The model centers on two flagship products, FemaSeed and FemaLift, and supports tighter education, faster feedback, and clearer sales tracking.
Reproductive endocrinology channel
Reproductive endocrinologists are a tightly defined route to Femasys Inc.’s fertility customers, since they treat the infertility population that includes the 1 in 6 adults affected globally. This specialized, clinic-based channel fits FemaSeed and related products because purchasing is concentrated in fertility centers, where a small number of physicians can drive repeat use and adoption.
Women’s healthcare organizations
Women’s healthcare organizations work as buying and distribution hubs for Femasys Inc., letting one provider group place product across multiple practices and expand reach fast. With women making up about 50.8% of the U.S. population, this channel helps scale access inside large women’s health networks and supports repeat use.
International distribution
FemVue is commercialized across 4 regions: the U.S., Europe, Canada, and Japan, so Femasys Inc. uses cross-border distribution to widen reach without building every local sales force. Distribution partners help extend market coverage and speed access in each channel.
That setup matters for a small medtech company: one product can move through regional regulatory and commercial paths, while partners handle local selling and service.
- 4 active geographies
- Partner-led market expansion
- Cross-border commercialization
Office-based clinical settings
Office-based clinical settings are the natural channel for Femasys Inc. because its products are built for clinician use and for non-surgical procedures done in outpatient offices, not hospitals. This matches the company’s low-acuity positioning and supports faster adoption where patient flow is high and procedure time stays short.
Clinician-led, office-based use
Fits non-surgical delivery model
Best for outpatient patient flow
Femasys Expands Through Clinic-Based Women’s Health Channels
Femasys Inc. uses specialist, clinic-based channels: OB-GYNs, reproductive endocrinologists, and women’s health groups, with sales centered in office settings for non-surgical use. FemVue is also distributed across 4 geographies: the U.S., Europe, Canada, and Japan, showing a partner-led route to wider reach.
| Channel | Data |
|---|---|
| Geographies | 4 |
| Use setting | Office-based |
| Buyer type | OB-GYNs and fertility clinics |
Customer Segments
Obstetrician-gynecologists
Femasys Inc. names obstetrician-gynecologists as direct product customers, and their adoption is the main path to scale in contraception, fertility, and office-based diagnostics. The American College of Obstetricians and Gynecologists represents more than 60,000 OB-GYNs and subspecialists, so winning this channel can materially expand procedure volume and revenue reach.
Reproductive endocrinologists
Reproductive endocrinologists are a core fertility customer for Femasys Inc. because their practice sits at the center of infertility care, a market where ASRM says about 1 in 6 people face infertility. FemaSeed fits their clinical focus on tubal and infertility-related treatment, so the product maps directly to the patient flow they already manage.
Allied healthcare professionals
Femasys supplies products to allied healthcare professionals who support women’s health procedures and patient care, not just specialist physicians. That widens the clinician base in a U.S. workforce with over 5 million registered nurses and about 178,000 physician assistants, helping reach more care settings.
Women’s healthcare provider organizations
Women’s healthcare provider organizations are direct B2B buyers for Femasys Inc. They can standardize one device or protocol across multiple clinics, which supports repeat institutional orders and steadier demand. In the U.S., women’s health care touches roughly 84 million women of reproductive age, making scale across systems meaningful.
- Direct institutional customer
- Standardized clinic-wide use
- Repeat purchasing potential
International women’s health markets
FemVue serves international women’s health markets in Europe, Canada, and Japan, giving Femasys Inc. three non-U.S. customer segments and reducing reliance on one geography. This matters because Europe, Canada, and Japan together add higher-value reimbursement paths and broader physician adoption outside the U.S.
- Europe, Canada, Japan
- Non-U.S. customer segments
- Broader demand base
Femasys Targets a Massive Women’s Health Market
Femasys Inc. targets OB-GYNs, reproductive endocrinologists, and allied women’s health clinicians as the main users of its office-based devices, with institutional buyers helping standardize use across clinics. The channel is backed by large care pools, including 60,000+ OB-GYNs and subspecialists, 5 million+ registered nurses, and about 178,000 physician assistants.
Its fertility focus is tightly linked to real demand, since ASRM says about 1 in 6 people face infertility. Internationally, FemVue extends the segment mix into Europe, Canada, and Japan, broadening adoption beyond the U.S.
| Segment | Why it matters | Key data |
|---|---|---|
| OB-GYNs | Primary device users | 60,000+ clinicians |
| Fertility specialists | Core FemaSeed users | 1 in 6 infertility |
| International markets | Non-U.S. growth base | Europe, Canada, Japan |
Cost Structure
Research and development
Research and development is core to Femasys Inc.’s model because device innovation drives its contraception, infertility, and diagnostics pipeline. R&D spending funds new product design, testing, and iterative improvements, so it is the main engine behind future product approvals and commercialization.
Clinical development
Clinical development is a core cost driver for Femasys Inc. because each product and candidate needs clinical validation, and trial design, site management, monitoring, and data work can quickly become the biggest R&D expense. These costs fund the evidence regulators, doctors, and investors need before wider adoption.
Regulatory compliance
Regulatory compliance is a recurring cost line for Femasys Inc.: FDA review, quality-system work, validation testing, and post-market surveillance all need ongoing staff time and documentation. In 2025/2026, these costs stayed in every market, with U.S. FDA 510(k) submissions carrying user fees in the tens of thousands of dollars and PMA reviews far higher.
Manufacturing and supply
Femasys Inc. must produce sterile non-surgical devices in steady lots, so manufacturing, packaging, and logistics stay core costs. With a small commercial base, each shipped unit has to absorb more fixed plant and quality costs, and international distribution adds customs, labeling, and channel-control work.
- Steady production keeps unit costs down.
- Packaging and freight are core costs.
- Global sales add customs and compliance.
Sales and commercialization
Sales and commercialization for Femasys Inc. need clinical sales staff, provider training, and account management, so this line pushes SG&A higher as the company expands beyond one market. Multi-country rollout adds local education, regulatory support, and field coverage, which lifts fixed operating costs before revenue scales.
- Commercial team drives clinician adoption.
- Training raises near-term operating expense.
- Global rollout adds country-level costs.
Femasys’ High Fixed Costs Keep Cash Burn Elevated
Femasys Inc.’s cost structure is dominated by R&D, clinical work, FDA compliance, and small-batch sterile manufacturing; these fixed-heavy costs keep cash burn high until sales scale. 2026 FDA 510(k) user fees add another recurring layer, so commercialization spend and quality control stay material as the product base expands.
| Cost item | 2025/2026 impact |
|---|---|
| R&D and clinical trials | Main cash driver |
| Regulatory and quality | Recurring fixed cost |
| Manufacturing and sales | Rises with rollout |
Revenue Streams
Device sales to providers
Femasys sells women’s health devices directly to OB-GYNs and allied professionals, so provider purchases are a core revenue stream. In FY2025, this channel remained central to commercialization, with sales tied to clinic adoption and repeat ordering across its women’s health portfolio.
Infertility product sales
FemaSeed is positioned for infertility care, so infertility product sales directly feed Femasys Inc.'s reproductive health line. The stream fits fertility specialist demand, especially with infertility affecting about 10% of women ages 15-44 in the U.S.
Diagnostic product sales
FemCerv is a biopsy device and FemEMB is a sampling candidate, so diagnostic sales can turn each procedure into product revenue. If Femasys Inc. wins broad clinical use, these tools can add recurring sales and deepen the women’s health portfolio.
International FemVue sales
FemVue’s international sales span 4 markets—U.S., Europe, Canada, and Japan—so Femasys Inc. can earn revenue beyond one geography. That wider reach supports a multi-country revenue stream, and the company can scale with each market’s uptake as it expands commercial access in 2025/2026.
- 4 active markets
- Revenue diversification
- Cross-border sales growth
Non-surgical technology commercialization
Femasys Inc. monetizes multiple non-surgical technologies, led by its commercial portfolio and new launches, so each added indication can lift total sales. In 2025, the company kept building out FemBloc and other product lines, which supports more than one revenue stream instead of a single-product model.
- Multiple products, multiple sales lines
- New launches can widen adoption
- Portfolio mix reduces single-product risk
Femasys Revenue Grows on Diverse Devices and Global Markets
Femasys Inc. earns revenue mainly from direct device sales to OB-GYNs and fertility specialists, with 2025 growth tied to FemaSeed, FemVue, FemCerv, and FemEMB adoption. The mix spans infertility, biopsy, sampling, and women’s health diagnostics, plus sales in 4 active markets, so revenue is spread across more than one product and geography.
| Revenue stream | 2025/2026 signal |
|---|---|
| Provider device sales | Core channel |
| Infertility products | FemaSeed demand |
| Diagnostics and sampling | FemCerv, FemEMB |
| International sales | 4 active markets |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.